A clinical study for TAE in combination with anlotinib, oxaliplatin and raltitrexed in the sequential treatment of middle or advanced primary liver cancer (PLC)

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900023191

Enrollment

Unknown

Registered

2019-05-16

Start date

2019-06-10

Completion date

Unknown

Last updated

2019-05-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heaptocellular Carcinoma,HCC

Interventions

Experimental group:TAE in combination with anlotinib, oxaliplatin and raltitrexed

Control group:Symptomatic treatment

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Clinical diagnosis, image examination or pathological test indicate the patients have middle or advanced primary liver cancer (PLC); 2. The patients carry measurable lesions (CT scan=2cm). Time for image diagnosis of measurable lesions <15 days; 3. Aged 18 to 70 years; 4. Karnofsky score =60; 5. Expected life =3 months; 6. Possible follow-up visit; 7. Normal heart function, kidney function and blood routine Liver function Child-Pugh: A or B class; 8. The ethics committee of the hospital where the patients stay ratified the informed consent signed by the patients.

Exclusion criteria

Exclusion criteria: 1. The patients have other malignant tumors; 2. The patients are accompanied by severe active infections or serious heart, liver, kidney and hematopoietic diseases; 3. The patients have no measurable or estimable lesions; 4. Non-compliant patients

Design outcomes

Primary

Measure	Time frame
ORR;	—

Secondary

Measure	Time frame
DCR;mOS;mPFS;AE;SR;	—

Countries

China

Contacts

Public ContactShen Yongqi

Center Hospital of Liutie

waldensgold@outlook.com+86 13878138979

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026